These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 27623022)
1. Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015). Singh IP; Shah P Expert Opin Ther Pat; 2017 Jan; 27(1):17-36. PubMed ID: 27623022 [TBL] [Abstract][Full Text] [Related]
2. 1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design. Faheem ; Karan Kumar B; Venkata Gowri Chandra Sekhar K; Chander S; Kunjiappan S; Murugesan S Expert Opin Drug Discov; 2021 Oct; 16(10):1119-1147. PubMed ID: 33908322 [No Abstract] [Full Text] [Related]
3. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Martin-Liberal J; Judson I Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190 [TBL] [Abstract][Full Text] [Related]
4. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575 [No Abstract] [Full Text] [Related]
5. Trabectedin: Supportive care strategies and safety profile. Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812 [TBL] [Abstract][Full Text] [Related]
6. Trabectedin in soft tissue sarcomas. Petek BJ; Loggers ET; Pollack SM; Jones RL Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274 [TBL] [Abstract][Full Text] [Related]
7. Trabectedin for the treatment of breast cancer. D'Incalci M; Zambelli A Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307 [TBL] [Abstract][Full Text] [Related]
8. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]. Gennigens C; Jerusalem G Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081 [TBL] [Abstract][Full Text] [Related]
9. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? Le Cesne A Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726 [TBL] [Abstract][Full Text] [Related]
10. Trabectedin. Chuk MK; Balis FM; Fox E Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073 [No Abstract] [Full Text] [Related]
17. Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution. Daupin J; Paubel P; Fillon J; Debrix I; Soares DG; Lotz JP J Chemother; 2016 Dec; 28(6):494-499. PubMed ID: 27535294 [TBL] [Abstract][Full Text] [Related]
18. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667 [TBL] [Abstract][Full Text] [Related]
19. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword. Reichardt P Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309 [No Abstract] [Full Text] [Related]
20. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Le Cesne A; Reichardt P Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]